Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

IGC Pharma (IGC) Other Operating Expenses (2016 - 2017)

IGC Pharma (IGC) has disclosed Other Operating Expenses for 4 consecutive years, with -$691139.0 as the latest value for Q1 2017.

  • On a quarterly basis, Other Operating Expenses rose 51.44% to -$691139.0 in Q1 2017 year-over-year; TTM through Dec 2017 was -$691139.0, a 72.72% increase, with the full-year FY2017 number at -$1.8 million, up 35.86% from a year prior.
  • Other Operating Expenses was -$691139.0 for Q1 2017 at IGC Pharma, down from -$111960.0 in the prior quarter.
  • In the past five years, Other Operating Expenses ranged from a high of -$111960.0 in Q4 2016 to a low of -$1.4 million in Q1 2016.
  • A 4-year average of -$682428.9 and a median of -$618938.5 in 2015 define the central range for Other Operating Expenses.
  • Biggest YoY gain for Other Operating Expenses was 70.45% in 2016; the steepest drop was 60.24% in 2016.
  • IGC Pharma's Other Operating Expenses stood at -$593845.0 in 2014, then soared by 36.19% to -$378928.0 in 2015, then skyrocketed by 70.45% to -$111960.0 in 2016, then crashed by 517.31% to -$691139.0 in 2017.
  • Per Business Quant, the three most recent readings for IGC's Other Operating Expenses are -$691139.0 (Q1 2017), -$111960.0 (Q4 2016), and -$614474.0 (Q3 2016).